A Phase 2, Randomized, Open-label Study of Gemcitabine/Cisplatin Plus Cemiplimab (REGN2810, Anti-PD-1) With or Without Fianlimab (REGN3767, Anti-LAG-3) for Organ Preservation in Patients With Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT).

The article focuses on a clinical trial investigating the effectiveness of drug gemcitabine/cisplatin plus cemiplimab, with or without fianlimab, in treating bladder cancer. It explains that participants are randomly assigned to receive either the full regimen or a combination without fianlimab, followed by a series of treatments and evaluations, including repeat tumor resections and imaging.